NanoViricides is trading higher in pre-market at $1.48 (+5.71%) after receiving Democratic Republic of Congo regulatory approval on August 10, 2026, to begin a Phase II trial of NV-387 oral gummies for Bundibugyo Ebola and other Ebola viruses.
- Om Sai Clinical Research will oversee the study.
- Patient dosing is expected to begin soon.